Read by QxMD icon Read


Renata R Urban, Todd C Pappas, Rowan G Bullock, Donald G Munroe, Vinicius Bonato, Kathy Agnew, Barbara A Goff
OBJECTIVE: To assess the performance of a symptom index (SI) and multivariate biomarker panel in the identification of ovarian cancer in women presenting for surgery with an adnexal mass. STUDY DESIGN: Prospective study of patients seen at a tertiary medical center. Following consent, patients completed an SI and preoperative serum was collected for individual markers (CA 125) and a second-generation FDA-cleared biomarker test (MIA2G). Results for the SI and MIA2G were correlated with operative findings and surgical pathology...
June 18, 2018: Gynecologic Oncology
Sung Bin Park, Min-Jeong Kim, Kyoung Ho Lee, Yousun Ko
OBJECTIVE: To retrospectively evaluate the clinical, pathological, and imaging features of ovarian serous surface papillary borderline tumors (SSPBTs). METHODS: Imaging features were analyzed, including the tumor size, laterality, tumor spread and the presence of ascites. Morphological nature (encased normal ovary, characteristics on MRI) and contrast enhancement (increased flow on Doppler US) were also evaluated. Clinical and pathological features, such as tumor markers (CA 125), treatment methods, outcomes on follow-up, and surgical staging, were analyzed...
June 11, 2018: British Journal of Radiology
Ângela Melo, Renata Veríssimo, Margarida Farinha, Nuno Nogueira Martins, Francisco Nogueira Martins
The major purpose of this article was to compare the discriminative value of different algorithms and serum biomarkers in the differential diagnosis of adnexal masses. We performed a retrospective study with 247 women with adnexal neoplasia, submitted to surgical treatment and with a histological diagnosis. The evaluation of the area under the curve (AUC) for isolated CA-125 and HE4, and for ROMA and RMI-II, showed a better specificity of HE4 and RMI-II in premenopausal women. In the postmenopausal group, ROMA and RMI-II were the algorithms with a better performance...
June 8, 2018: Journal of Obstetrics and Gynaecology: the Journal of the Institute of Obstetrics and Gynaecology
Tamara Knific, Katja Vouk, Andrej Vogler, Joško Osredkar, Manuela Gstöttner, René Wenzl, Tea Lanišnik Rižner
AIM: To evaluate preoperative levels of CA-125 and HE4 in patients with endometriosis-like symptoms and to construct diagnostic models. PATIENTS: Prospective case-control study included 124 endometriosis patients and 97 control patients. MATERIALS & METHODS: Logistic regression was used to construct diagnostic models based on serum biomarker levels and clinical data. RESULTS: A model with CA-125, BMI, information on cysts and dyspareunia had an area under the curve value of 0...
June 5, 2018: Biomarkers in Medicine
Daniel Martingano, Kayla Cagle-Colon, Jeanine Chiaffarano, Alan Marcus, Diana Contreras
Background: While the combination of a pelvic mass, very high serum level of CA-125, chest adenopathy, and ascites is concerning for advanced-stage ovarian cancer, the etiology of such a presentation can be due to disseminated pelvic tuberculosis. Case: A 67-year-old para 2 African-American woman presented with abdominal pain and shortness of breath. Subsequent CT and MR imaging demonstrated chest adenopathy, a pelvic mass, omental caking, and ascites. The patient underwent diagnostic laparoscopy with biopsy revealing noncaseating granulomas and subsequent tissue culture revealed Mycobacterium tuberculosis...
2018: Case Reports in Obstetrics and Gynecology
Evgenia Halkia, George Chrelias, Charalambos Chrelias, Jesus Esquivel
Ovarian cancer peritoneal carcinomatosis requires a multimodal-treatment approach. Current treatment considerations are analyzed in this update and include the management of recurrent malignant ascites and the understanding of its pathophysiology, the role of peritoneal washing cytology in detecting peritoneal metastases, capsular invasion and ovarian cancer histologic type, interpretation of pretreatment Ca-125 levels at different time points of ovarian cancer therapeutic management, characteristics of 10-year survivors of high-grade ovarian cancer, and the role of lymphadenectomy in ovarian cancer peritoneal carcinomatosis...
2018: Gastroenterology Research and Practice
Jae Hoon Lee, Jae Yen Song, Kyong Wook Yi, Sa Ra Lee, Dong-Yun Lee, Jung-Ho Shin, SiHyun Cho, Seok Kyo Seo, Sung Hoon Kim
This study aimed to assess whether dienogest (DNG) is also effective in patients with recurrent endometriosis based on multicenter data of 121 women who were clinically diagnosed as having recurrent endometriosis and treated for more than 24 weeks with DNG (2 mg daily). We evaluated the changes in endometriosis-associated pain scores (visual analog scale [VAS]), serum cancer antigen 125 (CA-125) levels, and endometrioma sizes following DNG medication in these women along with adverse events associated with DNG medication...
January 1, 2018: Reproductive Sciences
Rachel Grisham, Kathleen N Moore, Michael S Gordon, Wael Harb, Gwendolyn R Cody, Darragh F Halpenny, Vicky Makker, Carol Aghajanian
PURPOSE: Epithelial ovarian cancer (EOC) is a molecularly diverse disease. Mitogen-activated protein kinase kinase (MEK) inhibition targets tumors harboring mitogen-activated protein kinase (MAPK) pathway alterations and enhances paclitaxel-induced apoptosis in EOC. This phase Ib study evaluated the MEK inhibitor binimetinib combined with paclitaxel in patients with platinum-resistant EOC. EXPERIMENTAL DESIGN: Patients received intravenous (IV) weekly paclitaxel with oral binimetinib in three different administration schedules...
May 29, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Hero A Abdurrahman, Ariana Kh Jawad, Shahla K Alalalf
BACKGROUND: Preoperative differentiation between benign and malignant masses can be challenging. The aim of this research was to evaluate the performance of a modified multivariate index assay (MIA) in detecting ovarian cancer and to compare the effectiveness of gynecologist assessment, cancer antigen (CA) 125, and MIA for identifying ovarian masses with high suspicion of malignancy. RESULTS: This prospective observational study included 150 women with ovarian masses who underwent surgery in the Maternity Teaching Hospital from December 2014 to May 2016...
May 29, 2018: Journal of Ovarian Research
Eleonora Ghisoni, Dionyssios Katsaros, Furio Maggiorotto, Massimo Aglietta, Marco Vaira, Michele De Simone, Gloria Mittica, Gaia Giannone, Manuela Robella, Sofia Genta, Fabiola Lucchino, Francesco Marocco, Fulvio Borella, Giorgio Valabrega, Riccardo Ponzone
BACKGROUND: Optimal cytoreduction (macroscopic Residual Tumor, RT = 0) is the best survival predictor factor in epithelial ovarian cancer (EOC). It doesn't exist a consolidated criteria to predict optimal surgical resection at interval debulking surgery (IDS). The aim of this study is to develop a predictive model of complete cytoreduction at IDS. METHODS: We, retrospectively, analyzed 93 out of 432 patients, with advanced EOC, underwent neoadjuvant chemotherapy (NACT) and IDS from January 2010 to December 2016 in two referral cancer centers...
May 30, 2018: Journal of Ovarian Research
Kristina Lindemann, Bo Gao, Cristina Mapagu, Sian Fereday, Catherine Emmanuel, Kathryn Alsop, Nadia Traficante, Paul R Harnett, David D L Bowtell, Anna deFazio
OBJECTIVE: The aim of this study was to compare response rates and survival in women with "platinum resistant" epithelial ovarian cancer (EOC) who received further platinum-based or non‑platinum chemotherapy for treatment at first relapse. METHODS: Patients with high-grade EOC (including fallopian tube and peritoneal cancer) of all histologies recruited to the Australian Ovarian Cancer Study (AOCS) and treated with platinum-based primary chemotherapy were included...
May 25, 2018: Gynecologic Oncology
Rattapon Amampai, Prapaporn Suprasert
Objective: To determine the percentage of rising serum cancer antigen (CA-125) in singleton pregnant women whose ultrasonographical findings were normal. Methods: Singleton pregnant women who received antenatal care at our institute with a normal ultrasonographical examination in their first and/or second trimester were invited to participate in blood testing for CA-125. The conditions that might affect the CA-125 level were excluded. The normal level of CA-125 was defined as ≤35 U/ml...
2018: Obstetrics and Gynecology International
Juan Fernando Sánchez Vega, Magdali Del Rocío Murillo Bacilio, Adrián Santiago Vintimilla Condoy, Araceli Miroslava Palta González, José Alfredo Crespo Astudillo, Franklin Geovany Mora-Bravo
BACKGROUND: Cancer antigen (CA) 125 (CA-125) is used in ovarian cancer detection and monitoring, whose serum level has a positive correlation with tumor stage. The aim of this study was to obtain a prediction metastasis equation in a group of patients with ovarian cancer based on Ca-125. METHODS: A 2-group comparative observational study was conducted at a single oncologic institution (SOLCA) in Cuenca-Ecuador. All patients who were diagnosed with ovarian cancer between January 1996 and December 2016 were included in the current study...
May 24, 2018: BMC Cancer
Jun Zhu, Long Jiang, Hao Wen, Rui Bi, Xiaohua Wu, Xingzhu Ju
BACKGROUND: There are no effective biomarkers for surveillance in ovarian clear cell carcinoma (OCCC), and the value of carbohydrate antigen 125 (CA-125) is limited. We sought to determine the value of both carbohydrate antigen 19-9 (CA19-9) and CA-125 levels postoperatively on the prognosis for OCCC. METHODS: A total of 130 patients with OCCC who were consecutively treated by cytoreduction at Fudan University Shanghai Cancer Center were reviewed retrospectively...
May 18, 2018: International Journal of Gynecological Cancer
K Nahar, B Ferdous, N Akhter, P A Shamsunnahar, K Khatun, S A Begum, M A Aziz
Malignant transformation of ovarian endometriosis was first described in 1925 by Sampson; later on it has been described in extragonadal regions by few authors also. Ovarian endometrioid and clear cell carcinoma are highly associated with endometriosis. Here we present a case of malignant transformation of ovarian endometrioma into endometrioid adenocarcinoma and review the clinical and pathological features of these tumors. A 45-years old infertile woman diagnosed as a case of bilateral chocolate cyst with pelvic endometriosis underwent total hysterectomy with bilateral salpingo-oophorectomy...
April 2018: Mymensingh Medical Journal: MMJ
Yanzhen Lai, Xueping Wang, Tao Zeng, Shan Xing, Shuqin Dai, Junye Wang, Shulin Chen, Xiaohui Li, Ying Xie, Yuanying Zhu, Wanli Liu
Background: Effective biomarkers are essential to the differential diagnosis and severity assessment of non-small cell lung cancer (NSCLC). This study explored the use of the serum vascular endothelial growth factor (VEGF) levels as a biomarker with the aim of achieving better management of NSCLC. Methods: Serum VEGF levels were assayed via enzyme-linked immunosorbent assay in 180 patients with NSCLC, 136 patients with benign pulmonary nodules, and 119 healthy controls. We additionally detected the serum concentration of three traditional biomarkers-carcinoembryonic antigen (CEA), cancer antigen (CA)-125, and cytokeratin 19 fragments (Cyfra 21-1)-to comparatively evaluate the efficiency and diagnostic value of VEGF in patients with NSCLC...
2018: Journal of Cancer
Longyi Chen, Xiuwei Yang, Xiariwana Abasi, Gulinaer Shapaer, Ayinuer Aizimu, Shuping Zhang, Yingxiang Wan, Xiamuxi Kamaer, Tuoluniayi Tuerxun, Reyihanguli Abula, Qingyue Zhang
PURPOSE: To explore the clinical value of the level of human epididymis protein 4 (HE4) in serum in the diagnosis, prediction of postoperative recurrence and prognosis of epithelial ovarian cancer (EOC). METHODS: A total of 103 EOC patients and 121 individuals with benign ovarian lesions were selected. All of them were admitted to our hospital between January 2013 and January 2014 as group A (EOC, n=103) and group B (benign ovarian lesions, n=121), respectively...
March 2018: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
Yuan Yang, Jing-Cheng Hao, Yuan Chen, Yi Liu, Qi-Bing Xie, Geng Yin
OBJECTIVE: To investigate the relationship between tumor related markers and the presence of interstitial lung disease (ILD) in dermatomyositis (DM) patients as well as potential serum markers for accompanied ILD. METHODS: Fifty-nine DM patients were included,including 30 patents with ILD. Serum level of anti-transcription intermediary factor1-γ (TIF1-γ) and tumor-associated antigens (TAAs) were detected to analyze the correlation of these markers with ILD. Meanwhile,the diagnostic value of these markers was evaluated by receive operating characteristic (ROC) curve analysis...
March 2018: Sichuan da Xue Xue Bao. Yi Xue Ban, Journal of Sichuan University. Medical Science Edition
Gbemisola E Osanyin, Kehinde S Okunade, Ayodeji Ayotunde Oluwole
BACKGROUND: Preeclampsia is a syndrome of unknown etiology characterized by hypertension, proteinuria, and/or organ dysfunction. CA125 is an antigenic determinant recognized by the murine monoclonal antibody OC125 quantified by radioimmunoassay. Its role in obstetrics is yet to be fully understood as most clinical trials advocating its uses are widely experimental in nature and unacknowledged. AIM: This study was done to assess the relationship between serum concentration of CA125 in normal pregnancies and those complicated with preeclampsia...
May 2018: Hypertension in Pregnancy
Juliette Phelippeau, Roman Rouzier, Martin Koskas
BACKGROUND/AIM: Recommendations for endometrial cancer (EC) follow-up after treatment include regular clinical examinations without further systematic investigation. The objectives of our study were to examine adherence to follow-up guidelines in patients who underwent surgery for EC and identify associated variables. PATIENTS AND METHODS: Patients who underwent surgery for EC between 2005 and 2014 were identified among the Echantillon Généraliste des Bénéficiaires...
May 2018: Anticancer Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"